Genmab Reaches $3M Milestone Payment in DuoBody Platform Collaboration with Janssen

Genmab A/S GNMSF announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. JNJ, triggering a $3 million milestone payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Janssen has optioned 11 programs out of a total of 20 programs under the bispecific DuoBody platform collaboration with Genmab. Including the collaboration with Janssen, Genmab has five commercial partnerships for its DuoBody technology. "This milestone is another step in the continued validation of our DuoBody technology. Our technology collaborations are a key part of Genmab's strategy to generate diverse revenue streams and we are very pleased with the continued rapid progress of the DuoBody programs in our collaboration with Janssen," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Today's news will not impact Genmab's 2015 financial guidance. About the DuoBody Technology Collaboration with Janssen Under the original July 2012 agreement, Janssen has the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations. Genmab received an upfront payment See full press release